Organovo (ONVO) Updates 'Investor' Section of Website

On January 22, 2014, Organovo Holdings, Inc. (AMEX: ONVO) announced that that in response to investor inquiries it has updated the “Investor” section of its website, including the section titled “Investor FAQ” located at http://www.organovo.com/investors/frequently-asked-questions. Below is the updated section (as of January 21, 2014): CURRENT TOPICS: Can you comment in regard to Kanagawa Associates? Through investor inquiries, Organovo became aware of a potential problem with Kanagawa Associates' representations of selling Organovo stock at a discount in October 2013. When we received inquiries we explained that we had no relationship with Kanagawa and that our stock was instead publicly traded through licensed broker/dealers. We believe that as a result of our expressed concerns and those of investors, several regulatory agencies including those in Japan and Scandinavia successfully posted warnings about Kanagawa in the territories they were operating, which to our knowledge did not include the United States. To the Company’s knowledge, Kanagawa never actually sold shares to any investors, but is alleged instead to have simply accepted wired funds and not returned them. The practice of “cold-calling” is explicitly defined on the Japanese Financial Services Agency website warning as this practice – not actually selling shares, but promising to do so and then simply keeping the funds. The Japanese site also lists a “cold-calling” firm named “Tesla Acquisition Corporation”, so we assume that Organovo is not the only stock that cold-callers have used as bait. However, Organovo is unaware of how any such activity taking place outside the equity markets and not involving a broker/dealer who could actually sell shares can be hypothesized to have a material impact on the trading price of a NYSE MKT stock that has an average trading volume of over $60M a day. What is Organovo’s institutional ownership? Organovo had very little institutional ownership in the early days of the stock prior to our uplisting to the NYSE MKT, but institutional holdings have grown since then. The company targeted a fully institutional round for its August, 2013 financing round that brought in $46.6M in investment. With the help of the highly regarded investment bankers at Lazard and Oppenheimer, we achieved this, attracting investment from top healthcare investors who have some of the best research teams in the market. Our institutional holdings are strong and we intend to continue outreach to institutional investors by conducting activities such as those at last year’s Piper Jaffray and Oppenheimer Conferences, and by holding ongoing meetings through multiple investment banks who make introductions to institutional investment funds. Do the company’s executives earn between $60-85k per year as described on some financial websites? No, those numbers were taken from the Company’s three-month transition report for the period from January 1, 2013 and ending March 31, 2013. As such, they represent quarterly cash compensation for our named executives.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• Boeing names Ryan Shedd as new SVP and controller
• Greenland approves rare earths license transfer to Greenland Mines